Institute of Applied Synthetic Chemistry, Vienna University of Technology, Getreidemarkt 9/163MC, Vienna, 1060, Austria.
Functional Polymer Materials, Chair for Advanced Materials Synthesis, Institute for Functional Materials and Biofabrication, Department of Chemistry and Pharmacy, Julius-Maximilians-Universität Würzburg, Röntgenring 11, Würzburg, 97070, Germany.
Adv Healthc Mater. 2021 Mar;10(6):e2001382. doi: 10.1002/adhm.202001382. Epub 2021 Jan 14.
For many decades, poly(2-oxazoline)s and poly(2-oxazine)s, two closely related families of polymers, have led the life of a rather obscure research topic with only a few research groups world-wide working with them. This has changed in the last five to ten years, presumably triggered significantly by very promising clinical trials of the first poly(2-oxazoline)-based drug conjugate. The huge chemical and structural toolbox poly(2-oxazoline)s and poly(2-oxazine)s has been extended very significantly in the last few years, but their potential still remains largely untapped. Here, specifically, the developments in macromolecular self-assemblies and non-covalent drug delivery systems such as polyplexes and drug nanoformulations based on poly(2-oxazoline)s and poly(2-oxazine)s are reviewed. This highly dynamic field benefits particularly from the extensive synthetic toolbox poly(2-oxazoline)s and poly(2-oxazine)s offer and also may have the largest potential for a further development. It is expected that the research dynamics will remain high in the next few years, particularly as more about the safety and therapeutic potential of poly(2-oxazoline)s and poly(2-oxazine)s is learned.
几十年来，聚（2-恶唑啉）和聚（2-恶嗪）这两种密切相关的聚合物家族一直处于研究领域的边缘，全球只有少数几个研究小组在研究它们。这种情况在过去五到十年发生了变化，据推测，这主要是由于第一个基于聚（2-恶唑啉）的药物偶联物的非常有前景的临床试验所引发的。聚（2-恶唑啉）和聚（2-恶嗪）的化学和结构工具箱在过去几年中得到了极大的扩展，但它们的潜力在很大程度上仍未被开发。具体来说，本文综述了基于聚（2-恶唑啉）和聚（2-恶嗪）的大分子自组装和非共价药物传递系统（如聚合物复合物和药物纳米制剂）的发展。这个高度动态的领域特别受益于聚（2-恶唑啉）和聚（2-恶嗪）提供的广泛的合成工具箱，并且可能具有进一步发展的最大潜力。预计在未来几年，随着对聚（2-恶唑啉）和聚（2-恶嗪）的安全性和治疗潜力的了解不断增加，研究动态将保持高位。
